
Donata Medaglini is Full Professor of Microbiology and Clinical Microbiology in the Department of Medical Biotechnologies and Vice-Rector of the University of Siena. She holds a PhD in Microbiology from the University of Genova. From 1992-1994, she was Research Associate in the Laboratory of Bacterial Pathogenesis and Immunology at The Rockefeller University (New York). From 1996-2001, she was non-tenured Professor of Microbiology at the University of Siena. In 2001-2003, she was National Expert at the European Commission, DG Research and Innovation. Since 2003, she has been Professor of Microbiology and Medical Microbiology at the University of Siena. From 2013-2020, she was the Italian Representative for “Nanotechnologies, Advanced Materials, Biotechnology, Advanced Manufacturing and Processing” in the Horizon 2020 EU Programme Committee. Her research activity is in the field of microbial immunity, vaccines and advanced immunization technologies. She is author/coauthor of several publications in international peer-reviewed journals (Orcid ID: 0000-0002-4585-7783). She is the coordinator of the H2020 project “Advancing a GMMA-based vaccine against invasive non-typhoidal salmonellosis through Phase I trial in Europe and sub-Saharan Africa” (Vacc-iNTS, www.vacc-intsproject.eu), the coordinator of the EDCTPII project “Pediatric Phase I/II age de-escalation dose finding study of a vaccine against invasive non-typhoidal salmonellosis in sub-Saharan Africa” (pedvac-ints.eu) and the Scientific Coordinator of the IMI2 project “Innovations to accelerate vaccine development and manufacture” (Inno4Vac www.inno4vac.eu). She has been the Scientific Coordinator of the FP7 High Impact project “Advanced Immunization Technologies” (ADITEC), the Coordinator of the IMI projects “Systems analysis of adult and pediatric responses to the VSV-ZEBOV Ebola vaccine” (VSV-EBOLPUS, www.vsv-eboplus.eu) and “Vaccine safety and immunogenicity signatures of human responses to rVSV-ZEBOV” (VSV-EBOVAC, www.vsv-ebovac.eu) and the Managing Entity Coordinator of the IMI project “Standardisation and development of assays for assessment of influenza vaccine correlates of protection” (FLUCOP, www.flucop.eu).